Nadine C. Lamla

Lead the global indication and commercialization strategy for obrixtamig (DLL3/CD3 T-cell engager) from pivotal-stage development through launch readiness and global indication launch. Oversee the global marketing team and chair the Global Indication Team, aligning cross-functional stakeholders to drive strategic decisions and execution.

Led the global commercial strategy for obrixtamig (DLL3/CD3 T-cell engager) with accountability across commercial functions and direct leadership of global marketing team. Chaired the Global Brand Value Team, driving cross-functional strategy and execution from early clinical development through pivotal-stage and launch readiness. Concurrently led the immuno-oncology pipeline marketing team, overseeing a portfolio of T-cell engagers and immunomodulators.

Led global pipeline marketing for survodutide (GLP-1/GCGR agonist) across obesity and MASH within the Cardio-Renal-Metabolic therapeutic area.

Led the global cardiology strategy, launch planning, and commercialization for empagliflozin (SGLT2 inhibitor) across two heart failure indications, partnering across the Eli Lilly–Boehringer Ingelheim Alliance to deliver launches in co-promotion markets.

Built and led the Neurology Franchise, with responsibility for launch strategy and readiness across two brands, direct leadership of the marketing team, and chairing as brand lead the cross-functional brand team to drive successful launches and business performance

Directed the global marketing strategy and commercial activities for linagliptin, a DPP-4 inhibitor for type 2 diabetes, across co-promotion markets within the Eli Lilly and Boehringer Ingelheim Alliance.

Directed the Asia Pacific marketing strategy and commercial activities for canagliflozin (SGLT2 inhibitor for type 2 diabetes) launch, and led the cross-functional Integrated Brand Value Team to drive regional alignment and execution. Focus on Australia, China, South Korea and India.

Led the Primary Care, Women’s Health, Gastroenterology, Neurology, and Lifecycle Management franchises, with accountability for a product portfolio generating USD 300 million in annual affiliate sales. Directly managed the marketing team and drove integrated execution through the sales force, strategic partnerships, distribution and commercialization partners, media, and digital channels.

Led global marketing for the somatropin franchise and shaped the commercialization and launch strategy for a new patient delivery device.

Led the end-to-end commercialization of contraceptive patch across private and institutional markets, with direct leadership of the marketing team and responsibility for integrated execution across sales, digital, public relations, and direct-to-consumer channels in a regulated prescription enviornment.

Specialized in Marketing, Foreign Trade, Controlling and International Projects Award for Best Master Thesis of the Year 2003